Janssen Pharms., Inc. v. Tolmar, Inc. – Invega Sustenna® (Paliperidone Extended-Release Suspension)

May 9, 2024

Case Name: Janssen Pharms., Inc. v. Tolmar, Inc., Civ. No. 21-1784-WCB, 2024 WL 834762 (D. Del. Feb. 26, 2024) (Bryson, J.) – Drug Product and Patent(s)-in-Suit: Invega Sustenna® (paliperidone extended-release suspension); U.S. Patent No. 9,439,906 (“the ’906 patent”)….
By: Robins Kaplan LLP

Janssen Pharms., Inc. v. Tolmar, Inc. – Invega Sustenna® (Paliperidone Extended-Release Suspension)

Open Up Your Eyes: FDA Expects Real Transparency in ClinicalTrials.gov Disclosures

Top Five Things Lawyers and Neutrals Should Know About Using Artificial Intelligence